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Abstract. In 1994, I conjectured that insulin-degrading enzyme (IDE) acts as an inhibitor of 
malignant transformation by degrading insulin and thus preventing this major growth-
stimulatory hormone from binding and thereby inactivating the retinoblastoma tumor 
suppressor protein (RB). Ten years later, I discovered that a carboxyterminal RB amino acid 
sequence resembles the catalytic center of IDE. This structural homology raised the possibility 
that insulin degradation is a basic mechanism for tumor suppression shared by RB and IDE. 
Subsequently, a first immunohistochemical study on the differential expression of human IDE in 
normal tissues, primary tumors and their corresponding lymph node metastases further 
corroborated the initial conjecture on IDE being an antineoplastic molecule. In this report, it is 
shown that IDE harbors ankyrin repeat-like amino acid sequences through which it might bind 
and, as a result, antagonize the pro-inflammatory factor NF-kappaB as well as cyclin-dependent 
kinases (CDKs). As equally revealed here, IDE also contains 2 RXL cyclin-binding motifs which 
could contribute to its presumed inhibition of CDKs. These new findings suggest that IDE is 
potentially able to suppress both inflammation and oncogenesis by several mechanisms that 
ultimately ensure RB function. 
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Even after almost a century of intensive research, the details of insulin action and their relevance 
to major disease processes are still being elucidated. Towards a better understanding of this key 
molecule, investigations of its physical interactions with the insulin receptor, insulin-degrading 
enzyme (IDE) and retinoblastoma protein (RB) continue to provide important clues.  
Approximately 2 years after the initial description (1) of a potential complex formation 
between insulin and RB in 1992 which had suggested that insulin may directly inactivate 
(nuclear) RB similar to the effect of RB-binding viral oncoproteins, I inferred on the basis of the 
previously shown cytosolic interference of IDE with insulin´s nuclear translocation (2) and a 
partial structural homology between IDE and RB (3) that IDE represents a tumor suppressor 
preventing RB inactivation (3). 
A decade later, I detected in RB an amino acid sequence highly related to the catalytic 
center of IDE (4). This indicated a previously unknown potential for RB to degrade insulin and, 
moreover, significantly added to the validity of the initial IDE tumor suppressor hypothesis (3), 
thus collectively yielding the notion of insulin degradation possibly being a fundamental 
mechanism of tumor suppression (4). 
A subsequent experimental study on human breast cancer tissues further reinforced the 
concept of a growth-inhibitory IDE protein as its presence was demonstrated to be increased (in 
the sense of a host-defensive phenomenon) from non-malignant to neoplastic cells pertaining to 
primary tumors, yet decreased from primary tumors to their corresponding lymph node 
metastases (5). 
As it has been known for a long time that there is often a progression from (chronic) 
inflammation of tissues to their malignant transformation, I have now addressed the question as 
to whether insulin, IDE and RB may collectively be involved in this transition. A first hint in 
support of this anticipated relationship can be derived from the well-established association 
between (hyperinsulinemic) insulin resistance and inflammation (6). Such correlation implies 
that, as in other hyperinsulinemic states such as obesity and other potential premalignancies as 
well as during the aging process (7), intracellular insulin levels are probably increased in 
inflammatory states and this feature could be relevant to their pathogenesis. Accordingly, there 
is presumably also an IDE dysfunction under such conditions. 
In order to substantiate this assumption on an anti-inflammatory activity of IDE, I have 
searched for structural similarities between IDE and I-kappaB alpha, the principal inhibitor of 
the pro-inflammatory protein NF-kappaB in the cytoplasm. I thereby focused primarily on those 
I-kappaB alpha domains mediating its binding to NF-kappaB, specifically I-kappaB alpha´s 
ankyrin repeats, particularly the first such repeat that is of crucial importance in this binding (8). 
Interestingly, I have identified 4 ankyrin motif-like sequences in IDE (Fig. 1) that bear 
resemblance to ankyrin repeats in I-kappaB alpha and to alike amino acid patterns in the cyclin-
dependent kinase (CDK) inhibitor p16 in the latter of which they play a key role in this protein´s 
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binding to CDKs and its ensuing prevention of their phosphorylation and inactivation of RB (9). 
These findings suggest that IDE is potentially able to bind both NF-kappaB and CDKs by means 
of its putative ankyrin repeats and, as a result of these cytosolic encounters, inhibit their 
(nuclear) activity. Notably, this conclusion is supported by the fact that such amino acid 
signature enables I-kappaB alpha not only to block NF-kappaB, but also CDKs (10) and, 
conversely, p16 to abrogate CDK activity and NF-kappaB action (11). 
 
 
  DGFTPLHLAAQQGHLEIVKLLLERGADVNAQDK   human ANK consensus (9) 
 
  PSADWLATAAARGRVEEVRALLEAGALPNAPNS   human p1611-43  ANK1 
  YGRRPIQVMMMGSARVAELLLLHGAEPNCADPA human p1644-76  ANK2 
 
  DGDSFLHLAIIHEEKALTMEVIRQVKGDLAFLN  human I-kappaB alpha73-105  ANK1 
  LQQTPLHLAVITNQPEIAEALLGAGCDPELRDF  human I-kappaB alpha110-142  ANK2 
 
  RLAWLLHPALPSTFRSVLGARLPPPERLCGFQK  human IDE4-36  pot. ANK1 
  REYRGLELANGIKVLLMSDPTTDKSSAALDVHI  human IDE62-94  pot. ANK2 
  VSHEHLEGALDRFAQFFLCPLFDESCKDREVNA human IDE153-185  pot. ANK3 
  WRLFQLEKATGNPKHPFSKFGTGNKYTLETRPN human IDE199-231  pot. ANK4 
 
Fig. 1  Alignment of human ankyrin repeat consensus motif with similar domains in p16, I-kappaB alpha and IDE 
whereby 4 IDE regions are juxtaposed with 2 exemplary ankyrin signatures (from a total of more such 
patterns) in each of the former 2 proteins. Bold and underlined letters indicate highly conserved residues. 
Amino acid sequences are shown in one-letter code. "ANK" stands for ankyrin repeat motif and "pot." is the 
abbreviation for potential. 
 
  
 Moreover, I have identified (Fig. 2) that, intriguingly, IDE harbors 2 RXL cyclin-binding 
amino acid motifs that are similar to those present in the growth-suppressive RB family member 
p107 and the key CDK inhibitor p21 (12,13). 
 
 
  K R R L F G  human p107524-529 
  C R R L F G  human p2118-23 
  K R R L I  F  human p21154-159 
  L R L L M T  human IDE686-691 
  I  R R L D K  human IDE891-896 
 
Fig. 2 Alignment of RXL amino acid motifs in the human 
proteins p107, p21 and IDE. Crucial residues are 
highlighted in bold letters. Amino acid sequences are 
displayed in one-letter code. 
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 Beyond its 2 RXL motifs, IDE possesses a VXL motif within its second potential ankyrin 
repeat motif (Fig. 1). Interestingly, such VXL motifs have previously been shown to be 
comparable to RXL motifs in yielding CDK inhibition (14). 
 Furthermore, the fact that IDE contains not only such RXL/VXL motifs, but also the 
above-described putative ankyrin repeats hints at this protein being a p16/p21-like CDK 
inhibitor rather than a substrate for CDKs. 
 Along with potentially serving as domains for contacting CDKs and NF-kappaB, the 
candidate ankyrin motifs in IDE may equally contribute to a proper conformation of the IDE 
catalytic center (spanning IDE residues 108-112) for the proteolytic inactivation of insulin, 
conceivably such that the putative IDE ankyrin repeats 1 and 2 form one flank while repeats 3 
and 4 constitute the other flank of IDE´s enzymatic binding cleft for its substrate insulin. 
 Consequently, IDE binding of NF-kappaB is likely insufficient to counteract inflammation 
in those cases associated with abundant intracellular insulin as the latter may escape its 
degradation due to NF-kappaB´s masking of IDE´s catalytic center. As a result, insulin could 
move to the nucleus to physically disturb RB´s antiproliferative activity. Alternatively or 
additionally, insulin-bound, saturated IDE would be (sterically) unable to neutralize NF-kappaB. 
 In this context, it is noteworthy that the previously predicted (15) IDE contact sites for the 
multidrug resistance protein  P-glycoprotein (P-gp), i.e. IDE24-27 and IDE84-87, are located within 
the potential IDE ankyrin repeats 1 and 2, respectively (Fig. 1). This indicates that P-gp may 
engender (anti-cancer) drug resistance not only through releasing insulin (15), but also NF-
kappaB from IDE. This latter displacement could result from a direct competition between P-gp 
and NF-kappaB for the same IDE binding sites given that NF-kappaB harbors several 4-amino 
acid sequences (GADL, GDGL and GASL) in its p50 subunit as well as the signature GALL in its 
p65 subunit whereby all these tetrapeptides are highly similar to one of the anticipated (15) P-gp 
recognition sites for IDE, specifically the GAGL segment of P-gp (15). 
 Taken together, these novel findings point to a fascinating scenario in which IDE, besides 
degrading insulin in the cytosol, blocks NF-kappaB- hence preventing this factor´s activation of 
cyclin D/CDK complexes and their ensuing inactivation of RB (16)- as well as directly interferes 
with these complexes, thus protecting RB in multiple ways. Essentially, this report suggests that 
IDE- by controlling insulin-RB heterodimer-induced acceleration of cell growth, as previously 
outlined (17), and CDK-driven RB hyperphosphorylation, as proposed here- might represent a 
paradigm for uniting 2 distinct RB-defensive principles, i.e. insulin antagonism and CDK 
inhibition (18), in a single molecule with the potential to prevent both inflammation and cancer. 
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